Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Study of long-term outcomes of Mayo stage IIIb AL amyloidosis treated w/ daratumumab-based frontline therapy finds improved survival vs. pre-daratumumab cohorts (median OS 12.9 vs 4–6 months).”
Title: Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline Therapy
Authors: Simon Zhen, Sorina Nicoleta Bandelita, Divaya Bhutani, Mathew Maurer, Karan Wats, Yevgeniy Brailovsky, Michael Hughes, Jai Radhakrishnan, Daniel Coriu, Markus Mapara, Suzanne Lentzsch, Rajshekhar Chakraborty
You can read the Full Article on American Journal of Hematology.
You can find other articles featuring Robert Orlowski on OncoDaily.
